Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, Clinical Airway Research, 30625, Hannover, Germany.
German Center for Lung Research (DZL-BREATH), Hannover, Germany.
Sci Rep. 2024 Jan 19;14(1):1721. doi: 10.1038/s41598-024-51547-0.
Segmental instillation of lipopolysaccharide (LPS) by bronchoscopy safely induces transient airway inflammation in human lungs. This model enables investigation of pulmonary inflammatory mechanisms as well as pharmacodynamic analysis of investigational drugs. The aim of this work was to describe the transcriptomic profile of human segmental LPS challenge with contextualization to major respiratory diseases. Pre-challenge bronchoalveolar lavage (BAL) fluid and biopsies were sampled from 28 smoking, healthy participants, followed by segmental instillation of LPS and saline as control. Twenty-four hours post instillation, BAL and biopsies were collected from challenged lung segments. Total RNA of cells from BAL and biopsy samples were sequenced and analysed for differentially expressed genes (DEGs). After challenge with LPS compared with saline, 6316 DEGs were upregulated and 241 were downregulated in BAL, but only one DEG was downregulated in biopsy samples. Upregulated DEGs in BAL were related to molecular functions such as "Inflammatory response" or "chemokine receptor activity", and upregulated pro-inflammatory pathways such as "Wnt-"/"Ras-"/"JAK-STAT" "-signaling pathway". Furthermore, the segmental LPS challenge model resembled aspects of the five most prevalent respiratory diseases chronic obstructive pulmonary disease (COPD), asthma, pneumonia, tuberculosis and lung cancer and featured similarities with acute exacerbations in COPD (AECOPD) and community-acquired pneumonia. Overall, our study provides extensive information about the transcriptomic profile from BAL cells and mucosal biopsies following LPS challenge in healthy smokers. It expands the knowledge about the LPS challenge model providing potential overlap with respiratory diseases in general and infection-triggered respiratory insults such as AECOPD in particular.
经支气管镜向肺段内注入脂多糖 (LPS) 可安全地诱导人体肺部的短暂气道炎症。该模型可用于研究肺部炎症机制以及研究药物的药效分析。本研究旨在描述人类肺段 LPS 挑战的转录组图谱,并将其与主要呼吸系统疾病相关联。在 28 名吸烟的健康志愿者中,在进行肺段 LPS 注入和生理盐水对照之前,预先采集支气管肺泡灌洗液 (BAL) 和活检样本。注入 LPS 24 小时后,从受挑战的肺段采集 BAL 和活检样本。对 BAL 和活检样本中细胞的总 RNA 进行测序,并对差异表达基因 (DEGs) 进行分析。与生理盐水相比,LPS 挑战后 BAL 中有 6316 个 DEGs 上调,241 个 DEG 下调,但活检样本中只有一个 DEG 下调。BAL 中上调的 DEGs 与分子功能有关,如“炎症反应”或“趋化因子受体活性”,以及上调的促炎途径,如“Wnt-”/“Ras-”/“JAK-STAT”-信号通路。此外,肺段 LPS 挑战模型与五种最常见的呼吸系统疾病(慢性阻塞性肺疾病(COPD)、哮喘、肺炎、肺结核和肺癌)的某些方面相似,并与 COPD 的急性加重(AECOPD)和社区获得性肺炎有相似之处。总的来说,我们的研究提供了健康吸烟者接受 LPS 挑战后 BAL 细胞和黏膜活检的转录组图谱的广泛信息。它扩展了关于 LPS 挑战模型的知识,提供了与一般呼吸系统疾病以及特别是 AECOPD 等感染触发的呼吸系统损伤之间的潜在重叠。